We have located links that may give you full text access.
Early pharmacokinetic of ropivacaine without epinephrine after injection into the psoas compartment.
British Journal of Anaesthesia 2015 January
BACKGROUND: Large amounts of local anaesthetics (LA) are used during psoas compartment block (PCB), especially if combined with sciatic nerve block. Data regarding early pharmacokinetics of ropivacaine for PCB are lacking, notably when a vasoconstrictive agent has not been added.
METHODS: PCB was established in 11 patients using 150 mg ropivacaine without epinephrine. Free and total arterial plasma concentrations of ropivacaine were measured at nine time points during the following 30 min. Also total protein, albumin, and α1-acid glycoprotein concentrations were analysed.
RESULTS: Ropivacaine plasma concentrations were found in all patients within 30 s after injections. Maximum measured plasma concentrations were measured in all but two patients within the first 10 min. One patient experienced partial intravascular injection. Plasma concentrations showed wide inter-individual variability. Ranges of maximum measured plasma concentrations of total and free ropivacaine were 422-3905 and 5-186 ng ml(-1), respectively. The Pearson correlation between total and free concentrations was 0.96. No obvious relationship between concentrations of different plasma proteins (total protein, albumin, α1-acid glycoprotein) and ropivacaine concentrations was found. Maximal 5% of the measured ropivacaine was unbound. All blocks were successful and no signs of toxicity were observed.
CONCLUSIONS: Maximum measured plasma concentrations of ropivacaine after PCB must be expected within 10 min. Although plasma concentrations stayed below toxic thresholds, our study demonstrates the risk of this regional anaesthesia technique.
CLINICAL TRIAL REGISTRATION: The clinical study was not registered because enrolment of study patients occurred in 2006.
METHODS: PCB was established in 11 patients using 150 mg ropivacaine without epinephrine. Free and total arterial plasma concentrations of ropivacaine were measured at nine time points during the following 30 min. Also total protein, albumin, and α1-acid glycoprotein concentrations were analysed.
RESULTS: Ropivacaine plasma concentrations were found in all patients within 30 s after injections. Maximum measured plasma concentrations were measured in all but two patients within the first 10 min. One patient experienced partial intravascular injection. Plasma concentrations showed wide inter-individual variability. Ranges of maximum measured plasma concentrations of total and free ropivacaine were 422-3905 and 5-186 ng ml(-1), respectively. The Pearson correlation between total and free concentrations was 0.96. No obvious relationship between concentrations of different plasma proteins (total protein, albumin, α1-acid glycoprotein) and ropivacaine concentrations was found. Maximal 5% of the measured ropivacaine was unbound. All blocks were successful and no signs of toxicity were observed.
CONCLUSIONS: Maximum measured plasma concentrations of ropivacaine after PCB must be expected within 10 min. Although plasma concentrations stayed below toxic thresholds, our study demonstrates the risk of this regional anaesthesia technique.
CLINICAL TRIAL REGISTRATION: The clinical study was not registered because enrolment of study patients occurred in 2006.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app